{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:07:43Z","timestamp":1771956463812,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"24","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2018,7,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Mevalonate Kinase Deficiency (MKD, OMIM #610377) is a rare\nautosomal recessive metabolic and inflammatory disease. In MKD, defective function of the\nenzyme mevalonate kinase, due to a mutation in the MVK gene, leads to the shortage of mevalonate-\nderived intermediates, which results in unbalanced prenylation of proteins and altered\nmetabolism of sterols. These defects lead to a complex multisystem inflammatory and\nmetabolic syndrome.\n&lt;p&gt;\nObjective: Although biologic therapies aimed at blocking the inflammatory cytokine interleukin-\n1 can significantly reduce inflammation, they cannot completely control the clinical\nsymptoms that affect the nervous system. For this reason, MKD can still be considered an\norphan drug disease. The availability of MKD models reproducing the MKD-systematic inflammation,\nis crucial to improve the knowledge on its pathogenesis, which is still unknown.\nNew therapies are also required in order to improve pateints\u2019 conditions and their\nquality of life.\n&lt;p&gt;\nMethods: MKD-cellular models can be obtained by biochemical inhibition of mevalonatederived\nisoprenoids. Of note, these cells present an exaggerated response to inflammatory\nstimuli that can be reduced by treatment with zaragozic acid, an inhibitor of squalene synthase,\nthus increasing the availability of isoprenoids intermediates upstream the enzymatic\nblock.\n&lt;p&gt;\nResults: A similar action might be obtained by lapaquistat acetate (TAK-475, Takeda), a\ndrug that underwent extensive clinical trials as a cholesterol lowering agent 10 years ago,\nwith a good safety profile.\n&lt;p&gt;\nConclusions: Here we describe the preclinical evidence supporting the possible repositioning\nof TAK-475 from its originally intended use to the treatment of MKD and discuss its\npotential to modulate the mevalonate pathway in inflammatory diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867324666170911161417","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T07:53:56Z","timestamp":1531209236000},"page":"2783-2796","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice"],"prefix":"10.2174","volume":"25","author":[{"given":"Annalisa","family":"Marcuzzi","sequence":"first","affiliation":[{"name":"Department of  Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Loganes","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health - IRCCS \u201cBurlo Garofolo\u201d, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Celeghini","sequence":"additional","affiliation":[{"name":"Department of  Life Sciences, University of Trieste, Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Kleiner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Columbia University Medical Center, New York, NY, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/155492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/155492\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/155492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T09:47:33Z","timestamp":1608889653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/155492\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":0,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,7,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666170911161417","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}